Bayer's Brazilian Headache Deepens as $700M Market Hangs in the Balance

Brazilian prosecutors seek to ban glyphosate, threatening Bayer's agri-pipeline and adding to legal woes ahead of US Supreme Court decision and mounting debt.

Bayer is staring down a fresh legal threat in Latin America that could upend its agricultural ambitions just as a landmark US Supreme Court ruling looms. Brazilian prosecutors have filed a lawsuit seeking to completely ban glyphosate-based products, targeting not the company directly but the health regulator Anvisa and the Rio de Janeiro government. The move aims to block production, export, import, sale and use of glyphosate in the country — one of Bayer’s most important agri-markets.

The timing could hardly be worse. Bayer had been banking on the launch of a new herbicide based on the active ingredient Icafolinmethyl in Brazil, with a market introduction slated for 2028. The company expects annual sales of around €700 million from that single product in the country. A glyphosate ban would not only jeopardize that pipeline but risk triggering copycat litigation across neighbouring states, destabilising Bayer’s entire Latin American franchise.

Cash Drain Deepens

The Brazilian suit lands as Bayer’s balance sheet shows clear strain. Free cash flow in the first quarter of 2026 slumped to minus €2.32 billion, compared with minus €1.53 billion a year earlier, largely due to settlement payments of roughly €2.0 billion related to PCB and glyphosate cases. Net financial debt swelled to €32.5 billion by the end of March.

Operationally, the group delivered a solid performance. Currency-adjusted revenue rose 4.1% to €13.41 billion in the first quarter, while adjusted EBITDA climbed 9.0% to €4.45 billion. Earnings per share came in at €2.81. For the full year, management expects revenue between €44.5 billion and €46.5 billion, with adjusted EPS of €4.10 to €4.60.

Supreme Court Decision Days Away

In the US, Bayer is awaiting a decision from the Supreme Court in the case “Durnell”, expected in June. A favourable ruling could significantly reduce the legal overhang from thousands of Roundup-related lawsuits. JPMorgan analyst Richard Vosser sees potential for a 5% share-price uplift if the court sides with the company — less about new revenue and more about easing uncertainty.

But unanimity among the justices is far from certain. The proposed US class-action settlement carries capped payments of up to $7.25 billion over a maximum of 21 years, with an opt-out deadline set for 4 June 2026. A final approval hearing before Judge Timothy Boyer is scheduled for 9 July.

Pipeline Offers a Bright Spot

Amid the legal turmoil, Bayer’s pharma division is delivering positive news. Olema Oncology plans to launch a new clinical trial in the second half of 2026 combining Nubeqa (darolutamide) with other agents against prostate cancer. Nubeqa is one of Bayer’s key growth drivers, and expanding its approved indications would reduce the group’s reliance on its more troubled business lines.

Technicals Tell the Tale

The stock closed at €37.82 on Xetra on Tuesday, with Tradegate quotes on Wednesday morning at €37.67 bid and €37.75 offer. That places the shares roughly 2.7% below the 50-day moving average of €38.86. From the 52-week high of €49.17 hit in February, the stock has lost about 23%.

The coming weeks offer three pivotal events: the 4 June opt-out deadline, the Supreme Court ruling sometime in June, and the 9 July settlement hearing. Then attention shifts back to fundamentals, with second-quarter results due on 4 August. The average analyst estimate for full-year EPS stands at €4.37 — enough to show progress, but not enough to push the glyphosate question off the radar.